Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

• DOI: 10.1080/1120009x.2024.2330835
• Publication Date: 2024-03-18T11:00:44Z
• Authors: Hasan Cagri Yildirim; Caner Kapar; Baris Koksal; Mustafa Seyyar; Pervin Can Sanci; Murad Guliyev; Perihan Perkin; Mustafa Buyukkor; Sendag Yaslikaya; Nargiz Majidova; Merve Keskinkilic; Duygu Ozaskin; Tugay Avci; Tugce Kubra Gunes; Murat Arcagok; Alper Topal; Gul Sema Yildiran...; Gozde Kavgaci; Nilgun Yildirim; Ozde Melisa Celayir; Nilufer Avci; Ferit Aslan; Ali Alkan; Mert Erciyestepe; Muhammet Cengiz; Metin Pehlivan; Ahmet Gulmez; Ismail Beypinar; Tugba Basoglu Tuylu; Erkan Kayikcioglu; Elvin Chalabiyev; Serdal Turhal; Halil Goksel Guzel; Eyyup Ayas; Mustafa Sahbazlar; Ozgecan Dulgar; Hacer Demir; Tugba Yavuzsen; Vedat Bayoglu; Derya Kivrak Salim; Banu Ozturk; Feyyaz Ozdemir; Oguz Kara; Berna Oksuzoglu; Oznur Bal; Nebi Serkan Demirci; Mesut Yilmaz; Devrim Cabuk; Sercan Aksoy
• Keywords: Palbociclib; Fulvestrant

The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is MONALEESA-7 study, and data palbociclib limited. Data are also limited regarding whose dose was reduced due to neutropenia, most common side effect inhibitors. In our we aimed evaluate ribociclib reduction neutropenia progression-free survival. Our a multicenter, retrospective factors affecting survival (PFS) were examined diagnosed from 29 different centers receiving combination therapy containing or stage. 319 included study. mPFS for treated 26.83 months, those ribociclib, 29.86 months (p = 0.924). 32.00 who received dose, 25.96 could take initial there no statistical difference 0.238). Liver metastasis, using fulvestrant together inhibitor, ECOG PS 1 found be prognostic factor. No new adverse events observed. PFS over 27 used treatment, similar post-menopausal patients. We did not detect any between two inhibitors, showed that decrease inhibitor neutropenia.